2seventy Bio gains amid push from activist investor Engine Capital (update)
https://seekingalpha.com/news/4043994-2seventy-bio-gains-amid-push-from-activist-investor-engine-capital?source=feed_sector_healthcare
Dec 06, 2023 - Activist investor Engine Capital calls for changes at cancer therapy developer 2seventy Bio, pushing for a board refresh and new CEO appointment.
0
bluebird bio gene therapy lovo-cel for sickle cell disease has $3.1M cost (updated)
https://seekingalpha.com/news/4044803-bluebird-bio-gains-fda-approval-gene-therapy-lovo-cell-sickle-cell-disease?source=feed_sector_healthcare
Dec 08, 2023 - The FDA approves bluebird bio's gene therapy for sickle cell disease, boosting shares by 7%. Read more here.
0
Tourmaline Bio announces addition to NASDAQ Biotechnology Index
https://seekingalpha.com/news/4046988-tourmaline-bio-announces-addition-to-nasdaq-biotechnology-index?source=feed_sector_healthcare
Dec 15, 2023 - Tourmaline Bio (TRML) has been added to the NASDAQ Biotechnology Index, effective Dec.
0
bluebird bio announces proposed public offering of common stock
https://seekingalpha.com/news/4047685-bluebird-bio-announces-proposed-public-offering-of-common-stock?source=feed_sector_healthcare
Dec 18, 2023 - bluebird bio (BLUE) announces an underwritten public offering of $150M of its common stock, with proceeds to support gene therapies and general purposes.
0
Passage Bio stock climbs 9% on dementia study, program update
https://seekingalpha.com/news/4048762-passage-bio-stock-climbs-on-dementia-study-program-update?source=feed_sector_healthcare
Dec 20, 2023 - Passage Bio (PASG) shares surged 9% on encouraging Phase 1/2 data for gene therapy candidate PBFT02 in treating FTD-GRN, a type of early onset dementia. Read more here.
0
SomaLogic board urges shareholders to approve Standard Bio Tools merger
https://seekingalpha.com/news/4051340-somalogic-board-urges-shareholders-to-approve-standard-bio-tools-merger?source=feed_sector_healthcare
Dec 29, 2023 - SomaLogic’s (SLGC) board of directors has issued an open letter to stockholders urging them to vote for a proposed merger with Standard Bio Tools (LAB). Read more here.
0
Cabaletta Bio gains on FDA fast-track tags for lead asset
https://seekingalpha.com/news/4053209-cabaletta-bio-gains-fda-fast-track-tags-lead-asset?source=feed_sector_healthcare
Jan 08, 2024 - Cabaletta Bio's (CABA) stock rose after the FDA granted additional fast-track designations for its lead candidate in autoimmune conditions. Read more here.
0
Instil Bio hits four-month high on rising volumes
https://seekingalpha.com/news/4055774-instil-bio-stock-hits-four-month-high?source=feed_sector_healthcare
Jan 17, 2024 - Instil Bio (TIL) stock surged 21% on Wednesday after the biotech announced cost-cutting measures and a new partnership for its ITIL-306 program. Read more here.
0
Adicet Bio stock sinks on proposed public offering
https://seekingalpha.com/news/4057105-adicet-bio-stock-sinks-on-proposed-public-offering?source=feed_sector_healthcare
Jan 22, 2024 - Adicet Bio starts underwritten public offering, causing its stock to plummet by 15.3%.
0
Adicet Bio announces pricing of public offering
https://seekingalpha.com/news/4057425-adicet-bio-announces-pricing-of-public-offering?source=feed_sector_healthcare
Jan 23, 2024 - Adicet Bio announces the pricing of its public offering, with expected gross proceeds of $85.2M, to close on January 25, 2024.
0
Page 1>